The Latest Analyst Ratings for Legend Biotech
Portfolio Pulse from Benzinga Insights
In the last quarter, Legend Biotech (NASDAQ:LEGN) received 9 bullish ratings from analysts. The average 12-month price target for the company has increased by 14.16% to $84.67, with a high of $90.00 and a low of $77.00. No bearish or indifferent ratings were observed.
July 20, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Legend Biotech has received positive analyst ratings, with an increased average 12-month price target. This could potentially boost investor confidence and positively impact the stock price in the short term.
Analyst ratings often influence investor sentiment and can impact stock prices. The positive ratings and increased price target for Legend Biotech indicate a bullish outlook, which could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100